COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
25/06/2025
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, [...]
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
25/06/2025
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA [...]
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
25/06/2025
With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the " [...]
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
25/06/2025
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a [...]
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
25/06/2025
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage [...]
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
25/06/2025
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women-- ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- [...]
Commure Launches Commure Agents – AI Assistants That Fully Automate Physician Workflows
25/06/2025
Epic-integrated solution pioneers the industry’s shift from copilot to autopilot, ushering in the future of clinical automation MOUNTAIN VIEW, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Commure , a leading healthcare [...]
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25/06/2025
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for [...]
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25/06/2025
REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients [...]
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
25/06/2025
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to [...]
SmartVascular Dx™ Test: Enhancing Vascular Care in the Midwest
25/06/2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC ., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce [...]
Novartis announces expiration of Regulus Therapeutics tender offer
25/06/2025
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser [...]
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
25/06/2025
Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention [...]
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
25/06/2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
25/06/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug [...]
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
25/06/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible [...]
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
25/06/2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
25/06/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le [...]
OSE Immunotherapeutics provides an update on ongoing proceedings
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25 th , 2025, 8:00 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, [...]

Pages